Ovintiv Inc. (OVV)

Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.

Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.

Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.

Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.

Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.

Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.

Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.

OCF growth under 50% of CVE's 45.56%. Michael Burry might suspect questionable revenue recognition or rising costs.

FCF growth under 50% of CVE's 215.23%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.

Negative 10Y revenue/share CAGR while CVE stands at 48.12%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.

Negative 5Y CAGR while CVE stands at 48.12%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.

Negative 3Y CAGR while CVE stands at 48.12%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.

Negative 5Y OCF/share CAGR while CVE is at 21.31%. Joel Greenblatt would question the firm’s operational model or cost structure.

Negative 3Y OCF/share CAGR while CVE stands at 21.31%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.

Negative 10Y net income/share CAGR while CVE is at 145.96%. Joel Greenblatt sees a major red flag in long-term profit erosion.

Negative 5Y net income/share CAGR while CVE is 145.96%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.

Negative 3Y CAGR while CVE is 145.96%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.

Negative 5Y equity/share growth while CVE is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.

Negative 3Y equity/share growth while CVE is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.

Negative near-term dividend growth while CVE invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.

AR growth of 0.50% while CVE is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.

Negative asset growth while CVE invests at 1.47%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.

We have a declining book value while CVE shows 2.70%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.